<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264250</url>
  </required_header>
  <id_info>
    <org_study_id>D4120C00001</org_study_id>
    <nct_id>NCT01264250</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this early phase study, healthy male volunteers will be randomly assigned to one dose of
      either AZD2927 or placebo. The objective will be to assess the Safety,Tolerability and
      Pharmacokinetics of AZD2927.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AZD2927, at screening</measure>
    <time_frame>Monitoring of Adverse events, Electrocardiograms, vital signs, safety lab and ophtalmologic variables at screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD2927, day 1</measure>
    <time_frame>Monitoring of Adverse events, Electrocardiograms, vital signs, safety lab and ophtalmologic variables on day 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD2927, day 2</measure>
    <time_frame>Monitoring of Adverse events, Electrocardiograms, vital signs and safety lab on day 2.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD2927, day 3</measure>
    <time_frame>Monitoring of Adverse events, Electrocardiograms, vital signs, and safety lab on day 3.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD2927, at follow up</measure>
    <time_frame>Monitoring of Adverse events, Electrocardiograms, vital signs and safety lab at follow up.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 1</measure>
    <time_frame>Pharmacokinetic sampling will be performed day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 2</measure>
    <time_frame>Pharmacokinetic sampling will be performed day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmakokinetic for AZD2927 measured by Cmax, tmax, AUC, t1/2, CL and Vss, day 3</measure>
    <time_frame>Pharmacokinetic sampling will be performed day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2927</intervention_name>
    <description>Single dose of AZD2927</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy male subjects aged 18 to 45 years inclusive with suitable veins for
             cannulation or repeated venepuncture

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the day
             of dosing until 3 months after dosing with the Investigational Product (IP)

          -  Have a body mass index (BMI) between 19.0 and 30.0 kg/m2 and weight of at least 50.0
             kg and no more than 100.0 kg

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  History or presence of gastrointestinal, mental, cardiac, hepatic or renal disorder,
             or any other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs

          -  Abnormal vital signs, after 10 minutes supine rest

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the administration of IP

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang KÃ¼hn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Lunde, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mirjana Kujacic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug metabolism</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

